Cannabinergic pain medicine: A concise clinical primer and survey of randomized-controlled trial results

Clinical Journal of Pain

Volumn 29, Issue 2, 2013, Pages 162-171

  Aggarwal, Sunil K ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

cannabinoid; Cannabis; descending pain pathways; endocannabinoid; medical marijuana

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; MU OPIATE RECEPTOR; TRANS ISOMER OF DELTA 9 TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANALGESIA; ARTHRALGIA; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; DIABETIC NEUROPATHY; DISCOGENIC PAIN; DRUG HYPERSENSITIVITY; FIBROMYALGIA; GEOGRAPHY; HUMAN; MYOFASCIAL PAIN; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN; PHANTOM PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SPINAL CORD INJURY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VISCERAL PAIN;

CANNABINOIDS; FEMALE; HUMANS; MALE; PAIN; PAIN MANAGEMENT; PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872099163     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31824c5e4c     Document Type: Review

References (123)

1. Russo EB. The role of cannabis and cannabinoids in pain management. In: Weiner RS, ed. Pain Management: A Practical Guide for Clinicians. 6th ed. Boca Raton, FL: CRC Press; 2002:357-375.
2. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4:1614-1648.
3. O'Shaughnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis indica); their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of the Medical and Physical Society of Bengal 1838-1840; 71-102, 421-461. Available at: http://www. mikuriya. com/s1-1. pdf.
4. Mikuriya TH. Marijuana: Medical Papers 1839-1972. Oakland, CA: Medi-Comp Press; 1973.
5. Osler W. The Principles and Practice of Medicine: Designed for the Use of Practitioners and Students of Medicine. New York, NY: D. Appleton and Co. ; 1892:959.
6. Hare HA. Clinical and physiological notes on the action of cannabis indica. Therap Gaz. 1887;11:225-228.
7. Musto DF. The American Disease: Origins of Narcotic Control First Published in 1973. New York, NY: Oxford University Press; 1999.
8. Helmer J. Drugs and Minority Oppression. New York, NY: Seabury Press; 1975.
9. Lupien JC. Unraveling an American Dilemma: The Demonization Of Marihuana. Master's Thesis. Faculty of the Division of Humanities, Pepperdine University, 1995.
10. White W. Themes in chemical prohibition. In: William E. Link, et al, ed. Drugs in Perspective. Rockville, MD: National Drug Abuse Center/National Institute on Drug Abuse; 1979:117-182.
11. Mikuriya TH, Aldrich MR. Cannabis 1988: old drug, new dangers: the potency question. J Psychoactive Drugs. 1988; 20:47-55.
12. Aggarwal SK. Cannabis: a commonwealth medicinal plant, long suppressed, now at risk of monopolization. 87 Denv. U. L. Rev. Online 2010. Available at: http://www. denverlaw review. org/medical-marijuana/Accessed February 14, 2012.
13. "V. A. Easing Rules for Users of Medical Marijuana. " New York Times, July 24, 2010, p A1. Available at: http://www. nytimes. com/2010/07/24/health/policy/24veterans. html. Accessed February 14, 2012.
14. "U. S. Won't Prosecute in States That Allow Medical Marijuana. " New York Times, October 20, 2009, p A1. Available at: http://www. nytimes. com/2009/10/20/us/20cannabis. html?-r=2&scp=62&sq=&st=nyt. Accessed February 14, 2012.
15. Aggarwal SK, Carter GT, Sullivan MD, et al. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009; 5:153-168.
16. Conant V. Walters. (9th Cir 2002) 309 F. 3d 629, cert denied Oct. 14, 2003.
17. Aggarwal SK, Carter GT, Steinborn JJ. Clearing the air: what the latest Supreme Court decision regarding medical marijuana really means. Am J Hospice Palliat Med. 2005;22:327-329.
18. Russo EB, Mathre ML, Byrne A, et al. Chronic cannabis use in the Compassionate Investigational New Drug Program: an examination of benefits and adverse effects of legal clinical cannabis. J Cannabis Ther 2002; 2(1):3-57. Available at: http://www. maps. org/mmj/russo2002. pdf.
19. Label for Marinols. Label approved on 06/21/2006 for MARINOL, NDA no. 018651. Available at: http://www. fda. gov/ohrms/dockets/dockets/05n0479/05N- 0479-emc0004-04. pdf. Accessed February 14, 2012.
20. Label for Cesamets. Label approved on 05/15/2006 for CESAMET, NDA no. 018677. Available at: http://dailymed. nlm. nih. gov/dailymed/getFile. cfm?id=18369&type=pdf& name=bb582d64-0f51-11df-8a39-0800200c9a66. Accessed February 14, 2012.
21. United States Applied Names: http://www. ama-assn. org/ama1/pub/upload/ mm/365/nabiximols. pdf. Accessed February 14, 2012.
22. US Patent No. 7344736. PDF Available at: http://www. google. com/patents/download/7344736-Extraction-of-pharmaceutically-a. pdf?id=1N2oAAAAEBAJ&output=pdf&sig=ACfU3U0to N40EOzWpm-Gotsc81-6oZOd-Q. Accessed February 14, 2012.
23. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389-462. Available at: http://pharmrev. aspetjournals. org/cgi/reprint/58/3/389. pdf.
24. Hanus LO. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev. 2009;29:213-271.
25. McPartland JM, Pruitt PL. Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana. Altern Ther. 1999;5: 57-62.
26. McPartland J, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? In: Russo EB, Grotenhermen F, eds. Handbook of Cannabis Therapeutics: From Bench to Bedside. Binghamton, NY: Haworth Press; 2006:171-204.
27. Grotenhermen F. Practical hints. In: Grotenhermen F, Russo EB, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: Haworth Press; 2002:345-353.
28. Aggarwal SK, Kyashna-Tocha M, Carter GT. Dosing medical marijuana: rational guidelines on trial in Washington State. Medscape General Medicine 2007; 9(3):52. Available at: http://www. pubmedcentral. nih. gov/articlerender. fcgi?tool=pub med&pubmedid=18092058.
29. Grotenhermen F. Clinical pharmacokinetics of cannabinoids. In: Russo EB, Grotenhermen F, eds. Handbook of Cannabis Therapeutics: From Bench to Bedside. Binghamton, NY: Haworth Press; 2006:69-116.
30. Brenneisen R. Pharmacokinetics. In: Grotenhermen F, Russo EB, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: Haworth Press; 2002:67-72.
31. Fride E. The endocannabinoid-CB(1) receptor system in preand postnatal life. Eur J Pharmacol. 2004;500:289-297.
32. Grotenhermen F. Clinical pharmacodynamics of cannabinoids. In: Russo EB, Grotenhermen F, eds. Handbook of Cannabis Therapeutics: From Bench to Bedside. Binghamton, NY: Haworth Press; 2006:117-170.
33. Melamede R. Harm reduction-the cannabis paradox. Harm Reduction J. 2005;2:17. http://www. harmreductionjournal. com/content/2/1/17. Accessed February 14, 2012.
34. McPartland JM, Guy GW. The evolution of Cannabis and coevolution with the cannabinoid receptor-a hypothesis. In: Guy GW, Whittle BA, Robson PJ, eds. The Medicinal Use of Cannabis and Cannabinoids. Chicago, IL: Pharmaceutical Press; 2004:71-101.
35. Vettor R, Pagotto U, Pagano C, et al. Here, there and everywhere: the endocannabinoid system. J Neuroendocrinol. 2008;20:iv-vi.
36. Richardson JD. Cannabinoids modulate pain by multiple mechanisms of action. J Pain. 2000;1:2-14.
37. Baker D, Pryce G, Giovannoni G, et al. Therapeutic potential of cannabis. Lancet Neurol. 2003;2:291-298.
38. Vaughan CW, Christie MJ. Mechanisms of cannabinoid analgesia. In: Grotenhermen F, Russo EB, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: Haworth Press; 2002:89-99.
39. Holdcroft A. Pain therapy. In: Grotenhermen F, Russo EB, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: Haworth Press; 2002:181-186.
40. Di Marzo V. Cannabinoids. New York, NY: Kluwer Academic; 2004.
41. Sparling PB, Giuffrida A, Piomelli D, et al. Exercise activates the endocannabinoid system. Neuroreport. 2003;14:2209-2211.
42. McPartland JM, Giuffrida A, King J, et al. Cannabimimetic effects of osteopathic manipulative treatment. J Am Osteopath Assoc. 2005;105:283-291.
43. Degenhardt BF, Darmani NA, Johnson JC, et al. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. J Am Osteopath Assoc. 2007;107:387-400.
44. Chen L, Zhang J, Li F, et al. Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats. J Pain. 2009;10:732-739.
45. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Brit J Pharmacol. 2004;141:765-774.
46. Straiker A, Cannabinoids Mackie K. Electrophysiology, and Retrograde Messengers: Challenges for the Next 5 Years. AAPS J. 2006;8:E272-E276.
47. Burns HD, Van Laere K, Sanabria-Boho? rquez S, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA. 2007;104:9800-9805.
48. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990; 87:1932-1936.
49. McPartland JM. The endocannabinoid system: an osteopathic perspective. J Am Osteopath Assoc. 2008;108:586-600.
50. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;7:713-737.
51. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153:263-270.
52. Joy JE, Watson SJ, Benson JA. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy of Sciences, Institute of Medicine; 1999.
53. Wang T, Collet J, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. Can Med Assoc J. 2008; 178:1669-1678.
54. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735-744.
55. Mikuriya TH. Cannabis: A unique immunoanalgesic. Poster at the 2006 American Pain Society Meeting, San Antonio, CA.
56. Advisory Council on the Misuse of Drugs. Further consideration of the classification of cannabis under the Misuse of Drugs Act 1971. Home Office, London, Dec. 2005. Available at: http://www. homeoffice. gov. uk/acmd1/cannabis-reclass-2005?view=Binary. Accessed February 14, 2012.
57. Advisory Council on the Misuse of Drugs. Cannabis: Classification and Public Health. Home Office, London 2008. Available online at: http://www. homeoffice. gov. uk/acmd1/acmd-cannabis-report-2008?view=Binary. Accessed February 14, 2012.
58. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13. Available at: http://www. bio medcentral. com/1741-7015/2/13. Accessed February 14, 2012.
59. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9- tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;12:2748-2757.
60. Decoster J, van Os J, Kenis G, et al. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet. 2011;156B:363-369.
61. Melamede R. Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduction J. 2005;2:21.
62. Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung disease: a population-based study. CMAJ. 2009;180:814-820.
63. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012;307:173-181.
64. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006;10:1829-1834.
65. Data also presented as: Morgenstern H, Tashkin D, Greenland S, Zhang Z, Cozen W, Mack T. Marijuana use and cancers of the lung and upper aerodigestive tract: results of a case-control study. Presented at the International Cannabinoid Research Society (ICRS) 15th Annual Symposium on the Cannabinoids, Clearwater, Florida, June 24-27, 2005.
66. Also presented as: Tashkin DP, Zhang Z S. Greenland S, Cozen W, Mack T, Morgenstern H. Marijuana use and lung cancer: results of a case-control study. Presented at the American Thoracic Society International Conference, San Diego, CA, May 19-24, 2006.
67. Liang C, Marsit CJ, Nelson HH, et al. A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prev Res. 2009;2:759-768.
68. National Cancer Institute: PDQs Cannabis and Cannabinoids. Bethesda, MD: National Cancer Institute. Date last modified . Available at: http://www. cancer. gov/cancertopics/pdq/cam/cannabis/healthprofessional. Accessed July 31, 2011.
69. Abrams DI, Vizoso HP, Shade SB, et al. Vaporization as a smokeless cannabis delivery system: A pilot study. Clin Pharmacol Ther. 2007;82:572-57.
70. Russo E, Mathre ML, Byrne A, et al. Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal clinical cannabis. J Cannabis Ther. 2001;2:3-57.
71. Russo E, Guy G. The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234-246.
72. Morgan CJA, Schafer G, Freeman TP, et al. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Brit J Psychiatry. 2010;197:285-290.
73. Russo E. Taming THC: potential cannabis synergy and phytocannabinoid- terpenoid entourage effects. Brit J Pharmacol. 2011;163:1344-1364.
74. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 2004;74:1317-1324.
75. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9:254-264.
76. Aggarwal SK, Carter GT, Sullivan MD, et al. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag. 2009; 5:257-286.
77. Abrams DI, Couey P, Shade SB, et al. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011; 90:844-851.
78. Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids. 2010;5(special issue):1-21.
79. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4:245-259.
80. Martn-Sa nchez E, Furukawa TA, Taylor J, et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009;10:1353-1368.
81. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 "N of 1" studies. Anaesthesia. 2004;59:440-452.
82. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253.
83. Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology. 2005;48:1164-1171.
84. Svendsen KB, Jensen TS, Bach FW. Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis-secondary publication. Ugeskr Laeger. 2005; 167:2772-2774.
85. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812-819.
86. Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain-a randomized controlled trial. Wien Klin Wochenschr. 2006;118:327-335.
87. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol. 2006;253:1337-1341.
88. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12:639-645.
89. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebocontrolled trial. Neurology. 2007;68:515-521.
90. Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164-173.
91. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210-220.
92. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29:2068-2079.
93. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007; 107:785-796.
94. Frank B, Serpell MG, Hughes J, et al. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008;336:199-201.
95. Wilsey B, Marcotte T, Tsodikov A, et al. randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506-521.
96. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672-680.
97. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39:167-179.
98. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182:E694-E701.
99. Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther. 1978;23:397-401.
100. Maurer M, Henn V, Dittrich A, et al. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci. 1990;240:1-4.
101. Greenwald MK, ML Stitzer. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 2000;59:261-275.
102. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21-29.
103. Naef M, Curatolo M, Petersen-Felix S, et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003;105:79-88.
104. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290:1757-1762.
105. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517-1526.
106. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45:50-52.
107. Rintala DH, Fiess RN, Tan G, et al. Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil. 2010;89:840-848.
108. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebocontrolled study on 160 patients. Mult Scler. 2004;10:434-441.
109. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299-306.
110. Seeling W, Kneer L, Buchele B, et al. Delta(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain. Anaesthesist. 2006;55:391-400.
111. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006;53:769-775.
112. Esfandyari T, Camilleri M, Busciglio I, et al. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol. 2007; 293:G137-G145.
113. Redmond WJ, Goffaux P, Potvin S, et al. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin. 2008;24:1017-1024.
114. Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008;109:101-110.
115. Conte A, Bettolo CM, Onesti E, et al. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain. 2009;13:472-477.
116. Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169-172.
117. Selvarajah D, Gandhi R, Emery CJ, et al. Randomized placebo-controlled double-blind clinical trial of cannabisbased medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33:128-130.
118. Klein TW, Newton C, Friedman H. Cannabinoid receptors and the cytokine network. In: Friedman H, Madden JJ, Klein TW, eds. Drugs of Abuse, Immunomodulation, and AIDS. New York: Plenum Press; 1998:215-222.
119. Melamede R. Mechanisms in autoimmune diseases. In: Grotenhermen F, Russo EB, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: Haworth Press; 2002:111-119.
120. Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial. Ann Intern Med. 2003; 139:258-26.
121. Molina PE, Winsauer P, Zhang P, et al. Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retroviruses. 2011;27:585-592.
122. Smyth K, Affandi JS, McArthur JC, et al. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med. 2007;8:367-373.
123. Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5:e14433.